---
schema_version: "secwatch.filing_event.v1"
accession: "0001628280-25-047112"
form_type: "8-K"
ticker: "VNDA"
cik: "0001347178"
company_name: "Vanda Pharmaceuticals Inc."
filed_at: "2025-10-29T23:59:59+00:00"
generated_at: "2026-05-17T01:36:17.020883+00:00"
event_type: "earnings"
sentiment: "negative"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Vanda Q3 revenue up 18% to $56.3M but net loss widens to $22.6M; guidance lowered

## Summary
- Total net product sales $56.3M (+18% YoY): Fanapt $31.2M (+31%), HETLIOZ $18.0M (+1%), PONVORY $7.0M (+20%).
- Net loss $22.6M (diluted EPS -$0.38) vs loss $5.3M (-$0.09) in Q3 2024.
- FY2025 guidance: revenue $210-$230M (prev. $210-$250M); year-end cash $260-$290M (prev. $280-$320M).
- Pipeline: Tradipitant NDA PDUFA Dec 30, 2025; Bysanti NDA Feb 21, 2026; Imsidolimab BLA filing expected Q4 2025.
- Cash $293.8M at Sep 30, 2025, down $80.9M from Dec 31, 2024 and $31.8M from Jun 30, 2025.

## SEC filing metadata
- accession: 0001628280-25-047112
- form_type: 8-K
- ticker: VNDA
- cik: 0001347178
- company_name: Vanda Pharmaceuticals Inc.
- filed_at: 2025-10-29T23:59:59+00:00
- event_type: earnings
- sentiment: negative
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1347178/000162828025047112/0001628280-25-047112-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1347178/000162828025047112/vnda-20251029.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001628280-25-047112
- JSON: https://secwatch.observer/filing/0001628280-25-047112.json
- Plain text: https://secwatch.observer/filing/0001628280-25-047112.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.